Indeed, the experience of several randomized control trials has been included in the most recent guidelines ( In patients with T2DM, the treatment with SGLT2-i has been associated with a reduction in hospitalization for heart failure and cardiovascular deaths, regardless of pre-existing cardiovascular disease ( Several studies ( This heterogeneity in CV benefits across the trials, also among studies in which drugs of the same class have been used, could be explained by different study designs (i.e
We dont know whats in these compounded substances
Improper storage can degrade the medication's active compounds, potentially reducing weight loss results and increasing side effects
Key highlights: Average weight loss of ~12.4% in Phase 3 trials Improvements in blood pressure, triglycerides, and waist circumference Oral formulation could significantly expand accessibility and patient adoption Approved for adults with obesity or overweight plus weight-related conditions This approval represents another major shift in the rapidly growing obesity therapeutics market and increases competition with injectable treatments like Wegovy
Moreover, serious adverse events and severe hypoglycaemia rates were comparable regardless of whether an SGLT2i was used, with P -heterogeneity values of 0.29 and 0.50, respectively
Patients with pre-existing mental health conditions should discuss concerns with healthcare providers to understand potential emotional effects more thoroughly
